- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01801657
The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Bronchiectasis is a chronic airway disease characterised by a vicious cycle of persistent bacterial colonization,inflammation and progressive tissue destruction.Patients with bronchiectasis frequently developed acute exacerbations characterised by acute worsening requiring changes in concomitant use of medication,with attendant adverse effects on their morbidity and health-related quality of life. The detailed pathogenesis of exacerbations of bronchiectasis, however, remains poorly understood.
Recent data suggested that airway infection and inflammation are important drivers of exacerbations,therefore the imbalance between chronic bacterial infection and host immune response may result in bronchiectasis exacerbations. Viral infection may be an important factor that leads to this events.It has been established that respiratory viruses are mainly responsible for the exacerbations of other chronic respiratory diseases, i.e. asthma, COPD and cystic fibosis. However, the data regarding prospective studies that sought to investigate the roles of viruses in acute exacerbation of bronchiectasis are lacking. Furthermore,the associations between viruses and bacteria during exacerbation need to be assessed. This study targets at indentifying the frenquency of common viral infections in adults with non-cystic fibrosis bronchiectasis and may shed light on the effects they have on clinical parameters,i.e. the length of exacerbated symptom to recovery,lung function, pulmonary inflammation, bacterial load and quality of life.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Rongchang Chen, MD
- Numero di telefono: 020-83062718
- Email: Chenrc@vip.163.com
Backup dei contatti dello studio
- Nome: Nanshan Zhong, MD
- Numero di telefono: 020-83062718
- Email: nanshan@vip.163.com
Luoghi di studio
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510000
- Reclutamento
- The First Affiliated Hospital of Guangzhou Medical University
-
Contatto:
- Rongchang Chen, MD
- Numero di telefono: 020-83062718
- Email: Chenrc@vip.163.com
-
Contatto:
- Nanshan Zhong, MD
- Numero di telefono: 020-83062718
- Email: nanshan@vip.163.com
-
Sub-investigatore:
- Yonghua Gao, PHD
-
Sub-investigatore:
- Gang Xu, PHD
-
Sub-investigatore:
- Weijie Guan, PHD
-
Sub-investigatore:
- Zhiya Lin, PHD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Age ≥ 18 years
- HRCT-diagnosed Bronchiectasis
- Capable of providing written informed consent
Exclusion Criteria:
- Patient judged to have poor compliance
- Cystic fibrosis bronchiectasis
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
---|
Bronchiectasis,stable
A patient was defined as stable if there was no exacerbation for the previous 4 wk
|
Bronchiectasis,exacerbations
Bronchiectasis exacerbations were defined by subjective and persistent(>24 h) deterioration in at least three respiratory symptoms, including cough, dyspnea, hemoptysis, increased sputum purulence or volume, chest pain (with or without fever), radiographic deterioration, systemic disturbances, or changes in chest auscultation
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The prevalence of respiratory virus infection in adults with bronchiectasis during a pulmonary exacerbation and when clinically stable.
Lasso di tempo: 1 year
|
Respiratory viruses in the nasal swab and sputum will be identified using the polymerase chain reaction(PCR)technique when clinically stable and during exacerbation.The following viruses will be tested for:influenza A,B(including influenza A H1N1),respiratory syncytial virus(RSV),Enterovirus,Parainfluenza 1-4,Rhinovirus,human Coronaviruses(subtypes OC43、229E、HKU1),human metapneumovirus,adenovirus, human bocavirus,chlamydia,mycoplasma.
|
1 year
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The effect of respiratory virus infection on systemic and pulmonary inflammatory markers.
Lasso di tempo: 1 year
|
Systemic and airway inflammatory cytokines including IL-1β、IL-6、IL-8、TNF-a were measured using a commercial multiplex bead-based assay.
|
1 year
|
The effect of respiratory virus on lung function
Lasso di tempo: 1 year
|
Spirometric indices in the present study is referred to as forced expiratory vilume in 1s(FEV1),forced vital capacity(FVC).Spirometry tests are carried out using a spirometer (COSMED, QUARK PFT, Italy).
All operation procedures meet the joint recommendation by ATS and ERS.
A total of at least 3 (not more than 8) spirometric maneuvers are performed, with the variation between the best two maneuvers of <5% or 200ml in FVC and FEV1.
The maximal values of FVC and FEV1 are reported.
|
1 year
|
The effect of respiratory virus infection on the bacterial load in bronchiectasis.
Lasso di tempo: 1 year
|
Type of bacterial infection, also referred to as potentially pathogenic organisms, and bacterial load, as expressed in cfu per mililiter
|
1 year
|
Time to recovery of respective symptom
Lasso di tempo: 1 year
|
The time from exacerbation onset by which a 3-d moving average was equal to or exceeded the baseline value
|
1 year
|
The effect of respiratory virus on quality of life in patients with bronchiectasis
Lasso di tempo: 1 year
|
Quality of life in patients with bronchiectasis were measured by St.George Respiratory Questionnaire、Leicester Cough Questionnaire and COPD assessment test during exacerbations,and then compared between virus-postive and virus-negative patients
|
1 year
|
To investigate if upper respiratory tract symptoms are associated with viral infections.
Lasso di tempo: 1 year
|
1 year
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Nanshan Zhong, MD, The First Affiliated Hospital of Guangzhou Medical University
- Investigatore principale: Rongchang Chen, MD, The First Affiliated Hospital of Guangzhou Medical University
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2009CB522109
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .